Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702492 · ClinicalTrials.gov registry record · Phase 1
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
A Phase 1 study, sponsored by Karyopharm Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02702492: Clinical Trial Phase 1 study, sponsored by Karyopharm Therapeutics.
NCT02702492 is a Phase 1 study that was terminated before completion, run by Karyopharm Therapeutics. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02702492, a Phase 1 study, was terminated before completion, sponsored by Karyopharm Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
Primary Outcome
The MTD was defined as the highest dose at which less than or equal to (\<=) 1 participant experienced a dose limiting toxicity (DLT) in Cycle 1. A DLT was defined as an adverse event (AE) or abnormal laboratory value occurring within the first 28 days of treatment of KPT-9274, excluding those clearly caused by underlying disease, disease progression, or external factors.
Interventions
- DRUG Nivolumab
- DRUG KPT-9274
- DRUG Niacin ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-06-08 |
| Est. Completion | 2021-01-26 |
| Phase | Phase 1 |
Why NCT02702492 stopped before completion
NCT02702492 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02702492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02702492 about?
NCT02702492 is a clinical study titled "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)". This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
What is the current status of trial NCT02702492?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-06-08. Estimated completion is 2021-01-26.
What interventions are being tested in trial NCT02702492?
The interventions under investigation include: Nivolumab (DRUG), KPT-9274 (DRUG), Niacin ER (DRUG).
Who is sponsoring clinical trial NCT02702492?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02702492's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI